BrainStorm Cell Therapeutics (OTCQB: BCLI) narrows Q3 2025 loss as ALS trial preps advance and cash runway tightens

BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) reported a smaller net loss in the third quarter of 2025, driven by reduced administrative costs and lower research and development spending, as the company continues to prioritize the clinical advancement of its lead cell therapy candidate NurOwn for amyotrophic lateral sclerosis. With regulatory clearance now secured from the United States Food and Drug Administration, the biotechnology firm is mobilizing its operational network to initiate the Phase 3b ENDURANCE study, a pivotal step toward potential biologics license application submission.

The American cell therapy company posted a net loss of approximately 2.1 million dollars for the three months ended September 30, 2025, compared to a loss of around 2.7 million dollars in the same period last year. The improvement was largely attributed to a significant drop in general and administrative expenses, which fell to 1.1 million dollars from 2 million dollars a year earlier. Research and development expenses also declined modestly, coming in at 899,000 dollars for the quarter compared to 1.04 million dollars in Q3 2024.

Despite these cost reductions, BrainStorm Cell Therapeutics remains in a precarious financial position, with just 5,000 dollars in cash and equivalents and 231,000 dollars in restricted cash on hand as of the end of September 2025. Total assets declined to 1.38 million dollars from 1.83 million dollars at the end of the previous fiscal year, while liabilities stood at 9.07 million dollars. The shareholder deficit increased slightly to 7.89 million dollars, reinforcing the urgent need for new capital or strategic collaboration to maintain operational momentum.

What is the strategic significance of NurOwn’s Phase 3b trial and how is the company aligning its roadmap?

NurOwn, an autologous mesenchymal stem cell-derived therapy engineered to secrete neurotrophic factors, is the central focus of BrainStorm Cell Therapeutics’ near-term growth strategy. The product candidate has previously completed a Phase 3 trial, and the upcoming FDA-cleared Phase 3b trial aims to generate additional confirmatory data necessary for a potential biologics license application.

The ENDURANCE trial is expected to enroll approximately 200 ALS patients across leading clinical centers in the United States. The study is divided into two parts: a 24-week double-blind, placebo-controlled treatment phase, followed by a 24-week open-label extension to evaluate longer-term safety and therapeutic durability. The primary endpoint will be the change in ALS Functional Rating Scale-Revised scores from baseline to Week 24.

A Citizen Petition filed by ALS patient advocates earlier this year urged the United States Food and Drug Administration to revisit the previous Phase 3 data. Although BrainStorm Cell Therapeutics was not involved in the petition, company executives welcomed it as an indicator of the unmet need in ALS and the persistent belief in NurOwn’s potential benefits. Industry analysts view the Phase 3b study as a high-stakes inflection point that will determine the product’s regulatory fate.

Management has indicated that a conference call and webcast for investors will be held either in the fourth quarter of 2025 or the first quarter of 2026 to outline further trial-related updates. Operational readiness across clinical sites and manufacturing partners has reportedly been progressing, supported by ongoing engagement with regulators.

How do the Q3 financial statements reflect BrainStorm’s operational discipline and capital needs?

BrainStorm Cell Therapeutics managed to shrink its net loss for the third quarter even as it prepares for a large-scale clinical trial. Operating loss declined to 2.04 million dollars, down from 3.04 million dollars in Q3 2024. General and administrative spending was the largest contributor to this improvement, decreasing by nearly 45 percent year-over-year. Research and development expenses fell modestly but continued to reflect the cost of advancing both NurOwn and the company’s proprietary exosome platform.

Financial income and expenses added 59,000 dollars to the quarterly loss, while fair value accounting for warrant liabilities had a neutral effect in the three-month period. For the nine months ended September 30, 2025, the company reported a total net loss of 7.87 million dollars, an improvement over the 8.65 million dollar loss in the same period last year.

Earnings per share narrowed sharply to 19 cents per share in Q3 2025, compared to 51 cents per share in Q3 2024. This was aided by the increase in outstanding shares following recent equity issuances, with the average share count used in the per-share calculation rising from 5.3 million to over 11 million. While the dilution eased per-share losses, it also highlighted the company’s reliance on equity funding to sustain operations.

The company’s balance sheet illustrates a concerning picture. Cash and equivalents fell to just 5,000 dollars, with restricted cash at 231,000 dollars. Short-term liabilities rose slightly to over 9 million dollars, with 6.4 million dollars in accounts payable and nearly 1.9 million dollars in employee-related obligations. The total shareholder deficit expanded to 7.89 million dollars, reinforcing the need for new capital raises, potential asset monetization, or licensing agreements in the near term.

What role does the exosome platform play in diversifying BrainStorm’s future product pipeline?

Alongside NurOwn, BrainStorm Cell Therapeutics is advancing a novel exosome-based platform designed to deliver therapeutic proteins and nucleic acids to diseased tissue. The platform is allogeneic and scalable, offering a contrast to the autologous nature of NurOwn. In the third quarter, the company received a Notice of Allowance from the United States Patent and Trademark Office for a foundational patent covering the exosome delivery technology.

This IP milestone strengthens the company’s broader regenerative medicine portfolio and may offer non-dilutive monetization opportunities in the future. Analysts following the cell and gene therapy sector believe that exosomes represent a next-generation delivery platform with growing interest from pharmaceutical companies, particularly for hard-to-treat neurodegenerative and autoimmune diseases.

BrainStorm has indicated that it will continue to explore preclinical development and potential partnerships for the exosome program while focusing the majority of its near-term operational energy on completing the NurOwn Phase 3b trial.

What should investors monitor heading into early 2026 as trial execution begins?

Investor focus is likely to remain on three key themes heading into the first half of 2026: progress in patient enrollment for the ENDURANCE trial, financing developments to extend runway, and signals of regulatory or strategic interest in NurOwn or the exosome platform. While the FDA clearance for the Phase 3b trial is seen as a positive regulatory signal, successful trial execution will depend on coordinated site activations, manufacturing timelines, and adherence to Special Protocol Assessment conditions.

Sentiment among institutional investors remains cautious given the company’s low cash reserves and high liabilities. Retail interest, particularly among ALS advocates and mission-driven investors, continues to support the stock despite its OTC listing status. Any positive interim data or business development announcements could shift sentiment, although dilution risk remains a concern due to the company’s capital structure.

With nearly 11 million shares outstanding and an accumulated deficit of 234.5 million dollars, BrainStorm Cell Therapeutics must demonstrate capital efficiency and scientific execution in the months ahead. If successful, the Phase 3b trial could not only revive regulatory momentum but also open the door to commercial partnerships or acquisition interest from larger neurology-focused biopharmaceutical players.

What are the most important takeaways from BrainStorm Cell Therapeutics’ Q3 2025 financial update and clinical strategy?

• BrainStorm Cell Therapeutics Inc. reported a narrowed net loss of 2.1 million dollars for Q3 2025, compared to 2.7 million dollars in the same quarter of 2024, supported by sharp reductions in general and administrative expenses.

• Cash and equivalents stood at just 5,000 dollars at the end of September 2025, with restricted cash at 231,000 dollars, highlighting an urgent need for new financing to support upcoming clinical operations.

• The company confirmed operational readiness for the Phase 3b ENDURANCE trial of NurOwn in ALS, which aims to enroll approximately 200 patients and support a future biologics license application.

• The clinical trial includes a 24-week randomized placebo-controlled phase followed by a 24-week open-label extension, with ALSFRS-R as the primary endpoint to assess functional decline.

• A Citizen Petition was filed with the United States Food and Drug Administration by ALS community members seeking renewed review of NurOwn’s efficacy data, which BrainStorm acknowledged as a sign of persistent patient interest.

• Net loss per share improved to 19 cents from 51 cents year-over-year due to both cost savings and a higher average share count following equity issuance.

• Total liabilities increased slightly to over 9 million dollars, while the shareholder deficit widened to 7.89 million dollars, with total assets declining from 1.83 million dollars to 1.38 million dollars over nine months.

• BrainStorm Cell Therapeutics is also advancing its allogeneic exosome platform for therapeutic payload delivery, backed by a newly allowed U.S. patent, as part of its diversification beyond NurOwn.

• Investors are expected to focus on trial enrollment updates, capital raising efforts, and early signs of efficacy or strategic collaboration as the company heads into 2026.

• The upcoming conference call in Q4 2025 or early Q1 2026 is likely to serve as a key milestone event for investor sentiment and regulatory progress tracking.